Risk Factors for Development of Clostridium Difficile Infection Due to BI/NAP1/027 Strain: a Meta-analysis
Overview
Authors
Affiliations
Objective: To identify risk factors for the development of Clostridium difficile infection (CDI) due to C. difficile BI/NAP1/027 strain.
Methods: PubMed and Scopus databases were searched for studies that sought to identify risk factors for CDI due to the BI/NAP1/027 strain. The technique of meta-analysis was applied.
Results: Five studies compared CDI BI/NAP1/027 patients to CDI patients infected with non-BI/NAP1/027 strains, one compared CDI BI/NAP1/027 patients to non-CDI patients, and one provided data for both comparisons. The meta-analysis showed that fluoroquinolones were associated with a higher risk of CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (odds ratio (OR) 1.96, 95% confidence interval (95% CI) 1.37-2.80). A trend towards a lower risk for CDI due to BI/NAP1/027 was observed with cephalosporins when compared to non-BI/NAP1/027 CDI (OR 0.70, 95% CI 0.46-1.07). Prior macrolides were not associated with a higher risk for CDI BI/NAP1/027 when compared with non-BI/NAP1/027 CDI controls (OR 0.88, 95% CI 0.44-1.78). Clindamycin administration was associated with a lower risk for CDI due to BI/NAP1/027 when compared to non-BI/NAP1/027 CDI (OR 0.24, 95% CI 0.12-0.48). Age over 65 years was associated with an increased risk of CDI BI/NAP1/027 compared to non-BI/NAP1/027 CDI (OR 1.77, 95% CI 1.31-2.38).
Conclusions: Fluoroquinolones and age over 65 years were associated with a higher risk of CDI due to the BI/NAP1/027 strain. Clindamycin was associated with a lower risk of CDI due to BI/NAP1/027.
Examining the impact of the COVID-19 pandemic on hospital-associated infection.
Ray M, Furuno J, Strnad L, Lofgren E, McGregor J Infect Control Hosp Epidemiol. 2024; :1-7.
PMID: 39429023 PMC: 11663470. DOI: 10.1017/ice.2024.128.
Stamateanu L, Plesca C, Miftode I, Badescu A, Manciuc D, Hurmuzache M Antibiotics (Basel). 2024; 13(5).
PMID: 38786189 PMC: 11117487. DOI: 10.3390/antibiotics13050461.
Influence of Antibiotic Exposure Intensity on the Risk of Clostridioides difficile Infection.
Ray M, Strnad L, Tucker K, Furuno J, Lofgren E, McCracken C Clin Infect Dis. 2024; 79(5):1129-1135.
PMID: 38743579 PMC: 11581687. DOI: 10.1093/cid/ciae259.
Monday L, Yazdanpaneh O, Sokolowski C, Chi J, Kuhn R, Bazzy K Glob J Qual Saf Healthc. 2023; 4(3):109-116.
PMID: 37261063 PMC: 10228994. DOI: 10.36401/JQSH-21-2.
Alves J, Yamaguti A, de Mendonca J, de Melo Gamba C, Fonseca C, Paraskevopoulos D Antibiotics (Basel). 2022; 11(9).
PMID: 36139942 PMC: 9495058. DOI: 10.3390/antibiotics11091162.